Upgrade to SI Premium - Free Trial

Baird Reiterates Outperform Rating and $102 PT on Sarepta Therapeutics (SRPT); Mgmt Upbeat on Exondys 51 Launch

March 1, 2017 6:52 AM
Baird analyst Brian Skorney reiterates Outperform rating and $102 price target on Sarepta Therapeutics (NASDAQ: SRPT), as management provided no ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles